Which has the lower trailing P/E, IDXX or ZTS?

ZTS has the lower trailing P/E: IDXX trades at 42.00 and ZTS at 12.85. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, IDXX or ZTS?

Over the past five years, IDXX grew revenue faster — IDXX at a 9.24% CAGR versus ZTS at 6.28%.

Does IDXX or ZTS pay a bigger dividend?

ZTS pays a dividend (2.66% yield), while IDXX has no payments in the available dividend history.

Is IDXX or ZTS more profitable?

ZTS runs the higher net margin — IDXX at 24.63% versus ZTS at 27.79%.

How have IDXX and ZTS total returns compared?

Over the past 10 years, IDXX delivered 19.84% and ZTS delivered 5.39% annualized total return. Past performance doesn't predict future results.

IDEXX Laboratories, Inc. (IDXX) vs Zoetis Inc. (ZTS)

A side-by-side comparison of IDEXX Laboratories, Inc. and Zoetis Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 29, 2026. Differences are shown without an overall score or investment verdict.

IDXX

IDEXX Laboratories, Inc.

$44.95B

$569.77HealthcareDelayed quote: Jul 29, 2026, 4:00 PM EDT

ZTS

Zoetis Inc.

$32.67B

$77.94HealthcareDelayed quote: Jul 29, 2026, 3:59 PM EDT

Total return — IDXX vs ZTS

growth of $100 · dividends reinvested · last 13y

IDXX +1043.1%ZTS +180.7%IDXX compounded faster

IDXX ZTS

IDXX vs ZTS: by the numbers

•IDXX is the larger company ($44.95B vs $32.67B market cap).
•ZTS trades at the lower trailing earnings multiple (12.85 vs 42.00 P/E), one valuation lens rather than an overall verdict.
•ZTS converts more revenue to profit (27.79% vs 24.63% net margin).
•IDXX grew revenue faster over the past five years (9.24% vs 6.28% CAGR).
•ZTS pays a dividend (2.66% yield), while IDXX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	IDXX	ZTS
P/E ratio	42.00	12.85
Forward P/E	38.89	11.27
P/S ratio	10.33	3.44
P/B ratio	29.53	10.13
PEG ratio	2.31	2.04
EV / EBITDA	30.13	9.86
FCF yield	2.35%	6.52%

Profitability

Metric	IDXX	ZTS
Gross margin	62.05%	70.75%
Operating margin	31.63%	37.57%
Net margin	24.63%	27.79%
ROE	70.38%	81.75%
ROIC	40.27%	21.54%

Dividends

Metric	IDXX	ZTS
Dividend yield	N/A	2.66%
Payout ratio	N/A	34.16%

Growth (annualized)

Metric	IDXX	ZTS
Revenue CAGR (5Y)	9.24%	6.28%
EPS CAGR (5Y)	14.07%	11.88%
FCF CAGR (5Y)	10.13%	4.90%
Total return CAGR (5Y)	-3.92%	-16.61%

Frequently asked

Which has the lower trailing P/E, IDXX or ZTS?: ZTS has the lower trailing P/E: IDXX trades at 42.00 and ZTS at 12.85. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, IDXX or ZTS?: Over the past five years, IDXX grew revenue faster — IDXX at a 9.24% CAGR versus ZTS at 6.28%.
Does IDXX or ZTS pay a bigger dividend?: ZTS pays a dividend (2.66% yield), while IDXX has no payments in the available dividend history.
Is IDXX or ZTS more profitable?: ZTS runs the higher net margin — IDXX at 24.63% versus ZTS at 27.79%.
How have IDXX and ZTS total returns compared?: Over the past 10 years, IDXX delivered 19.84% and ZTS delivered 5.39% annualized total return. Past performance doesn't predict future results.

Go deeper

Full IDXX analysis Full ZTS analysis Interactive comparison tool

Dig into the metrics

IDEXX Laboratories P/E ratio Zoetis P/E ratio IDEXX Laboratories dividend yield Zoetis dividend yield IDEXX Laboratories ROE Zoetis ROE IDEXX Laboratories operating margin Zoetis operating margin IDEXX Laboratories revenue growth Zoetis revenue growth IDEXX Laboratories free cash flow Zoetis free cash flow

IDEXX Laboratories & Zoetis appear in these rankings

Highest Dividend Yield Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 29, 2026.